Gentian Diagnostics AS (OSL:GENT) Moat Score: 0/10 (As of Jul. 06, 2026)


OSL:GENT Gentian Diagnostics AS OSL:GENT
73 GF Score
Price kr37.00
GF Value kr61.88
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Gentian Diagnostics AS Moat Score?

Gentian Diagnostics AS has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Gentian Diagnostics AS has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Gentian Diagnostics AS might have No Moat - No discernible moat.

Gentian Diagnostics AS  (OSL:GENT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Gentian Diagnostics AS Moat Score Related Terms

OSL:GENT
73GF Score
Gentian Diagnostics AS OSL:GENT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of kr37.00 is trading 40.2% below its estimated GF Value™ of kr61.88. GuruFocus considers Gentian Diagnostics AS to be Possible Value Trap.

Key valuation signals for OSL:GENT:

  • Moat Score: 0
  • GF Value™: kr61.88 vs. price of kr37.00 (40.2% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gentian Diagnostics AS Business Description

Other Exchanges GENTOo:Sweden6FK:Germany
Address Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
73GF Score

Get the complete analysis for OSL:GENT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr37.00
Price
kr61.88
GF Value